1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. Massachusetts >
  6. MannKind Acquires scPharmaceuticals

M&A Deal Summary

MannKind Acquires scPharmaceuticals

On August 25, 2025, MannKind acquired life science company scPharmaceuticals for 360M USD

Acquisition Highlights
  • This is MannKind’s 1st transaction in the Life Science sector.
  • This is MannKind’s largest (disclosed) transaction.
  • This is MannKind’s 1st transaction in the United States.
  • This is MannKind’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2025-08-25
Target scPharmaceuticals
Sector Life Science
Buyer(s) MannKind
Deal Type Merger
Deal Value 360M USD
Advisor(s) Leerink Partners (Financial)
Latham & Watkins (Legal)

Target

scPharmaceuticals

Burlington, Massachusetts, United States
scPharmaceuticals is a commercial-stage pharmaceutical company focused on redefining cardiorenal care with integrated treatments designed to address the unmet needs of patients. scPharmaceuticals was founded in 2013 and is headquartered in Burlington, Massachusetts.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

MannKind

Danbury, Connecticut, United States
Category Company
Founded 1991
Sector Life Science
Employees403
Revenue 286M USD (2024)
DESCRIPTION

MannKind focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. MannKind was formed in 1991 and is headquartered in Danbury, Connecticut.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Merger M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal